FTV Stock Analysis: Fortive | NYSE
Scientific & Technical Instruments | NYSE, USA | Market Cap: 17.615m USD | 12M Return: 19% | US34959J1088 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 106M
EPS Trend: -54.0%
Qual. Beats: 0
Rev. Trend: -77.3%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Fortive Corporation (NYSE: FTV) is an Everett, Washington-based industrial and healthcare technology company that was incorporated in 2015 and spun off from Danaher Corporation in July 2016. The company operates two main segments: Intelligent Operating Solutions, which provides instrumentation, software, and services for asset lifecycle management, condition monitoring, and worker safety across manufacturing, utilities, and other industrial end-markets (brands include Fluke, Industrial Scientific, Accruent, and ServiceChannel); and Advanced Healthcare Solutions, which supplies sterilization, instrument tracking, biomedical testing, radiation monitoring, and clinical workflow software (brands include ASP, Fluke Biomedical, Censis, Landauer, and Provation). As a constituent of the Industrials sector, Fortive follows a multi-brand, decentralized operating model that combines recurring software and services revenue streams with hardware-based measurement and safety products.
- Intelligent Operating Solutions margin expansion drives earnings beats
- Healthcare Solutions acquisition pipeline accelerates post-Vontier separation
- China industrial demand weakness pressures test and measurement revenue
| Net Income: 534.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 0.55 > 1.0 |
| NWC/Revenue: 7.19% < 20% (prev -1.01%; Δ 8.21% < -1%) |
| CFO/TA 0.09 > 3% & CFO 1.05b > Net Income 534.4m |
| Net Debt (3.24b) to EBITDA (1.19b): 2.73 < 3 |
| Current Ratio: 1.24 > 1.5 & < 3 |
| Outstanding Shares: last quarter (307.6m) vs 12m ago -9.98% < -2% |
| Gross Margin: 63.23% > 18% (prev 59.78%; Δ 3.45% > 0.5%) |
| Asset Turnover: 28.91% > 50% (prev 33.70%; Δ -4.79% > 0%) |
| Interest Coverage Ratio: 6.43 > 6 (EBIT TTM 793.5m / Interest Expense TTM 123.4m) |
| A: 0.03 (Total Current Assets 1.60b - Total Current Liabilities 1.29b) / Total Assets 11.6b |
| B: 0.49 (Retained Earnings 5.69b / Total Assets 11.6b) |
| C: 0.05 (EBIT TTM 793.5m / Avg Total Assets 14.9b) |
| D: 1.09 (Book Value of Equity 6.06b / Total Liabilities 5.55b) |
| Altman-Z'' = 3.27 = A |
| DSRI: 1.03 (Receivables 657.8m/912.2m, Revenue 4.32b/6.15b) |
| GMI: 0.95 (GM 59.78% / 63.23%) |
| AQI: 1.08 (AQ_t 0.84 / AQ_t-1 0.77) |
| SGI: 0.70 (Revenue 4.32b / 6.15b) |
| TATA: -0.04 (NI 534.4m - CFO 1.05b) / TA 11.6b) |
| Beneish M = -3.22 (Cap -4..+1) = AA |
As of October 21, 2026, the stock is trading at USD 58.36 with a total of 2,086,742 shares traded. Over the past week, the price has changed by +0.50%, over one month by +5.94%, over three months by -4.20% and over the past year by +18.95%.
Current recommended Stop Loss: 56.90 (which is 2.5% or 1.3 ATR below the current price).
Fortive has received a consensus analysts rating of 3.25. Therefore, it is recommended to hold FTV.
- StrongBuy: 3
- Buy: 1
- Hold: 10
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 62.8 | 7.6% |
P/E Trailing = 30.4105
P/E Forward = 17.2712
P/S = 4.0815
P/B = 2.8036
P/EG = 1.2896
Revenue TTM = 4.32b USD
EBIT TTM = 793.5m USD
EBITDA TTM = 1.19b USD
Long Term Debt = 3.51b USD (from longTermDebt, last quarter)
Short Term Debt = 899.5m USD (from shortTermDebt, last fiscal year)
Debt = 3.61b USD (from shortLongTermDebtTotal, last quarter) + Leases 100.6m
Net Debt = 3.24b USD (calculated: Debt 3.61b - CCE 374.2m)
Enterprise Value = 20.9b USD (17.6b + Debt 3.61b - CCE 374.2m)
Interest Coverage Ratio = 6.43 (Ebit TTM 793.5m / Interest Expense TTM 123.4m)
EV/FCF = 21.84x (Enterprise Value 20.9b / FCF TTM 954.9m)
FCF Yield = 4.58% (FCF TTM 954.9m / Enterprise Value 20.9b)
FCF Margin = 22.13% (FCF TTM 954.9m / Revenue TTM 4.32b)
Net Margin = 12.38% (Net Income TTM 534.4m / Revenue TTM 4.32b)
Gross Margin = 63.23% ((Revenue TTM 4.32b - Cost of Revenue TTM 1.59b) / Revenue TTM)
Gross Margin QoQ = 63.39% (prev 63.17%)
Tobins Q-Ratio = 1.80 (Enterprise Value 20.9b / Total Assets 11.6b)
Interest Expense / Debt = 3.42% (Interest Expense 123.4m / Debt 3.61b)
Taxrate = 10.39% (69.8m / 672.0m)
NOPAT = 711.1m (EBIT 793.5m * (1 - 10.39%))
Current Ratio = 1.24 (Total Current Assets 1.60b / Total Current Liabilities 1.29b)
Debt / Equity = 0.60 (Debt 3.61b / totalStockholderEquity, last quarter 6.06b)
Debt / EBITDA = 2.73 (Net Debt 3.24b / EBITDA 1.19b)
Debt / FCF = 3.39 (Net Debt 3.24b / FCF TTM 954.9m)
Total Stockholder Equity = 6.28b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.58% (Net Income 534.4m / Total Assets 11.6b)
RoE = 8.52% (Net Income TTM 534.4m / Total Stockholder Equity 6.28b)
RoCE = 8.11% (EBIT 793.5m / Capital Employed (Equity 6.28b + L.T.Debt 3.51b))
RoIC = 6.46% (NOPAT 711.1m / Invested Capital 11.0b)
WACC = 7.65% (E(17.6b)/V(21.2b) * Re(8.59%) + D(3.61b)/V(21.2b) * Rd(3.42%) * (1-Tc(0.10)))
Discount Rate = 8.59% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -96.41 | Cagr: -6.29%
[DCF] Terminal Value 73.10% ; FCFF base≈1.13b ; Y1≈993.6m ; Y5≈802.8m
[DCF] Fair Price = 31.65 (EV 12.9b - Net Debt 3.24b = Equity 9.65b / Shares 304.9m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -53.96 | EPS CAGR: -5.90% | SUE: 0.76 | # QB: 0
Revenue Correlation: -77.33 | Revenue CAGR: -10.04% | SUE: 0.07 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.71 | Chg30d=-0.07% | Revisions=+0% | Analysts=14
EPS current Year (2026-12-31): EPS=3.01 | Chg30d=-0.11% | Revisions=-17% | GrowthEPS=+11.2% | GrowthRev=+5.1%
EPS next Year (2027-12-31): EPS=3.25 | Chg30d=+0.01% | Revisions=-12% | GrowthEPS=+7.8% | GrowthRev=+3.8%
[Analyst] Revisions Ratio: -15% (up=4, down=6)